Introduction Bristol Myers Squibb (BMS) and Takeda have recently joined forces with several peers in an ambitious data-sharing venture to advance artificial intelligence (AI) in drug discovery according to Reuters. Alongside AbbVie, Johnson & Johnson (J&J), and Astex Pharmaceuticals, they will pool proprietary research data -- specifically, thousands

Executive Overview Pharmaceutical royalties occupy a complex regulatory landscape where classification depends fundamentally on structure rather than asset type. As of October 2025, no jurisdiction treats pharmaceutical royalties as a distinct regulated asset class. Instead, regulatory treatment hinges on whether royalties are packaged as direct bilateral contracts (typically outside securities

Complete Biotech Deals Report: September 29-October 5, 2025 Executive Summary The week of September 29-October 5, 2025, witnessed 19 distinct biotechnology transactions with total disclosed deal value exceeding $11.5 billion. This comprehensive analysis covers all major biotech news sources, press releases, and SEC filings, revealing a week

Introduction: The Promise of Invisible Assets In the modern economy, the most valuable assets often cannot be seen or touched. Intellectual property—patents, trademarks, copyrights, and proprietary technologies—now comprises an estimated 70-80% of a typical firm's value, yet these intangible assets traditionally don't appear

Investment Thesis and Business Strategy Ligand Pharmaceuticals operates a "royalty aggregation" business model, building a diversified portfolio of drug royalty interests and licensing assets. The investment thesis is that Ligand can generate stable cash flows from marketed products while maintaining upside from a broad pipeline of partnered drug

Congratulations to Kumquat Biosciences on its brilliant naming -- the kumquat is indeed a great fruit, known for its sweet-tart flavor and auspicious connotations. But beyond the playful name, Kumquat Biosciences (a privately held San Diego-based biotech founded in 2019) has quickly grown into a serious player in the

Executive Summary: CVR deployment reaches $35 billion across Q1-Q3 2025 transactions Contingent Value Rights (CVRs) have become integral to biotech M&A structuring, with deployment across $35 billion in transaction value through Q3 2025. Data indicates CVR inclusion in 29% of life sciences acquisitions, representing a structural shift

In a high-interest-rate environment (U.S. Fed Funds ~5.25–5.50% in 2024), traditional biotech funding has pulled back sharply (VC investment in life sciences fell ~60% from 2021 peaks) while royalty financing has surged ~45% annually. The appeal is clear: royalty deals offer non-dilutive capital

The AI drug discovery sector achieved its first major clinical validation in 2025 with Insilico Medicine's rentosertib becoming the first fully AI-discovered and designed drug to demonstrate positive Phase IIa results, marking a significant development for the industry. This breakthrough, published in Nature Medicine in June 2025,

Biotech dealmaking surged this week, from Pfizer’s $7.3 billion obesity acquisition to a run of licensing, royalty financings, and venture rounds. Disclosed upfronts exceeded $6 billion, with total potential deal values over $9 billion. The week highlights two trends: Big Pharma securing pipelines in obesity, CNS, and AI-